Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders

Current Neuropharmacology

Volumn 9, Issue 1, 2011, Pages 209-214

  Onaivi, E S ^a,b   Benno, R ^a   Halpern, T ^a   Mehanovic, M ^a   Schanz, N ^a   Sanders, C ^a   Yan, X ^a   Ishiguro, H ^b,c   Liu, Q R ^b   Berzal, A L ^d   Viveros, M P ^d   Ali, S F ^e  

^a WILLIAM PATERSON UNIVERSITY   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c Happoukai Medical Corporation   (Japan)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

9 THC; Autism; Behavior; BTBR T+tf J mice; Cannabinoid; Monoamines; MPTP; Psychostimulants

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 11 HYDROXYDRONABINOL; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABINOID; CANNABINOID 2 RECEPTOR; DOPAMINE; METHAMPHETAMINE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTISM; BEHAVIOR CHANGE; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DOPAMINE BRAIN LEVEL; FEMALE; FORCED SWIMMING TEST; FRONTAL CORTEX; GENE EXPRESSION; HIPPOCAMPUS; LOCOMOTION; MALE; MONOAMINERGIC SYSTEM; MOUSE; NEUROCHEMISTRY; NONHUMAN; RUNNING; SEROTONIN BRAIN LEVEL;

EID: 79953059982     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015911795017047     Document Type: Article

References (17)

1. King, B.H., Bostic, J.Q. An update on pharmacologic treatments for autism spectrum disorders. Child Adolesc. Psychiatr. Clin. N. Am., 2006, 15, 161-175.
2. Nickels, K.C., Katusic, S.K., Colligan, R.C., Weaver, M.S., Voigt, R.G., Barbaresi, W. J. Stimulant medication treatment of target behaviors in children with autism: A population-based study. J.Dev. Behav. Pediatr., 2008, 29, 75-81.
3. Robinson, P.D., Schutz, C.K., Macciardi, F., White, B.N., Holden, J.A. Genetically determined low maternal serum dopamine bhydroxylase levels and etiology of autism spectrum disorders. Am. J. Med. Genet., 2001, 100, 30-36.
4. Yrigollen, C.M., Han, S.S., Kochetkova, A., Babitz, B., Chang, J.T., Volkmar, F.R., Leckman, J.F., Grogorenko, E.L. Genes controlling affiliative behavior as candidate genes for autism. Biol. Psychiatry., 2008, 63, 911-916.
5. Page, D.T., Kuti, O.J., Prestia, C., Sur, M. Haplo insufficiency for pten and serotonin transporter cooperatively influences brain size and social behavior. Proc. Natl. Acad. Sci. USA, 2009, 106, 1989-1994.
6. Wang, K., Zhang, H., Ma, D., Bucan, M, Glessner, J.T., Abrahams, B.S., Salyakina, D., Imielinski, M., Bradfield, J.P., Sleiman, P.M.A, Kim, C.E., Hou, C., Frackelton, E. Hakonarson, H. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature, 2009, 459, 528-533.
7. Bill, B.R., Geschwind, D.H. Genetic advances in autism: heterogeneity and convergence on shared pathways. Curr. Opin. Genet. Dev., 2009, 19, 271-278.
8. Mehler, M.F., Purpra, D.P. Autism, fever, epigenetics and the locus coerulus. Brain Res. Rev., 2008, 59, 388-392.
9. Jones, J.R., Skinner, C., Friez, M.J., Schwartz, C.E., Stevenson, R.E. Hypothesis: Dysregulation of methylation of brain expressed genes on the X chromosome and autism spectrum disorders. Am. J. Med. Genet. Part A., 2008, 146A, 2213-2220.
10. Szyf, M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu. Rev. Pharmacol. Toxicol., 2009, 49, 243-263.
11. Crawley, J.N. Mouse behavioral assays relevant to the symptoms of autism. Brain Pathol., 2007, 17, 448-459.
12. Onaivi, E.S. Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. Int. Rev. Neurobiol., 2009, 88, 335-369.
13. Liu, Q.R., Pan, C.H., Hishimoto, A., Li, C.Y., Xi, Z.X, Llorente-Berzal, A., Viveros, M.P., Ishiguro, H., Arinami, T., Onaivi, E.S., Uhl, G.R. Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Gene Brain Behav., 2009, 8, 519-530.
14. Silverman, J.L., Tolu, S.S., Barkan, C.L., Crawley, J.N. Repetitive Self-Grooming Behavior in the BTBR Mouse Model of Autism is Blocked by the mGluR5 Antagonist MPEP. Neuropsychopharmacology, 2009, 1-14. (Online ahead of print).
15. Benno, R., Smirnova, Y., Vera, S., Liggett, A., Schanz, N. Exaggerated responses to stress in the BTBR T+tf/J mouse: An unusual behavioral phenotype. Behav. Brain Res., 2009, 197, 462-465.
16. Crespi, B., Stead, P., Elliot, M. Comparative genomics of autism and schizophrenia. Proc. Natl. Acad. Sci. USA, 2009, 1-6. (Online ahead of print).
17. Ishiguro, H., Horiuchi, Y., Ishikawa, M., Koga, M., Imai, K., Suzuki, Y., Morikawa, M., Inada, T., Watanabe, Y., Takahashi, M., Someya, T., Ujike, H., Iwata, N., Ozaki, N., Onaivi, E.S, Kunugi, H., Sasaki, T., Itokawa, M., Arai, M., Niizato, K., Iritani, S., Naka, I., Ohashi, J., Kakita, A., Takahashi, H., Nawa, H., Arinami, T. Brain cannabinoid CB2 receptor in schizophrenia. Biol. Psychiatry, 2010, 67, 974-982.